e19033 Background: Insurance status impacts access to cancer care and outcomes of cancer patients. Patients who are uninsured and those who are insured by Medicaid are less likely to receive cancer screening, more likely to present at later stages of disease, and more likely to die from cancer compared to those who are privately insured. It is unclear whether patients insured by Medicare have different outcomes than patients with private insurance. Methods: We undertook a retrospective analysis of patients treated in our practice from January 1, 2019 to March 31, 2019. Outcomes of solid tumor patients were tracked after treatment in the neoadjuvant or metastatic setting. Patients were stratified by their insurance status and we then compared treatment outcomes of patients with private insurance to those with Medicare. Results: We treated 86 patients from January 1, 2019 to March 31, 2019 including 63 women and 23 men with a median age of 62 years (range 22-88 years). Several types of malignancies were represented including 21 gynecologic cancers, 17 breast cancers, 11 lung cancers, 10 melanomas, 10 gastrointenstinal cancers, 7 lymphomas, 5 genitourinary cancers, and 5 other tumor types. Among our population, 48 patients had private insurance and 38 had Medicare. Thirty-four patients achieved either a complete response (CR) or partial response (PR), 24 with CR and 10 with PR. Of those who achieved a CR, 11 had Medicare and 14 had private insurance. Among those who achieved a PR, 5 had Medicare and 5 had private insurance. Conclusions: In this retrospective analysis, insurance type did not predict likelihood of achieving a complete or partial response to treatment. Other investigators have suggested that patients with Medicare have poorer outcomes than those with private insurance. One potential explanation for the discrepancy between their data and ours is that we have dedicated system designed to accelerate pre-certifications. Additional investigation is warranted to better understand these trends.